CorMedix to buy Heron's four hospital drugs for $145m cash plus shares
The 9 November agreement puts the upfront package at about $222.6m, with up to $55m more in earn-outs and royalties, and a close targeted for early 2027.
CorMedix has agreed to take over almost the entire asset base of Heron Therapeutics, adding a four-product portfolio of hospital-administered drugs. The two companies announced the binding agreement on 9 November 2026.
Heron's side of the bargain is $145m in cash and 14.58m CorMedix shares, which the summary of the deal puts at roughly $222.6m upfront. Heron may also receive up to $55m through earn-outs and royalties, although the terms of those payments were not detailed in the material available.
The portfolio comprises ZYNRELEF for postoperative pain, plus APONVIE, CINVANTI and SUSTOL. The last three address nausea and vomiting, either after surgery or as a result of chemotherapy. To pay for part of the cash element, CorMedix plans to draw $75m on a term loan from Pharmakon.
Completion is pencilled in for the first quarter of 2027. It requires clearance under the Hart-Scott-Rodino Act, the US premerger antitrust review regime, and approval from Heron's stockholders. Until then the products remain with Heron, and details such as marketing authorisation holder changes would follow only after closing.
Why it matters
- Roughly $75m of the cash component is to come from debt, so the buyer's financing depends in part on the Pharmakon term loan.
- Up to $55m in contingent payments means the final value to Heron's holders depends on future performance as well as the upfront terms.
- Hospital contracting and market-access teams face a pending change of ownership across all four products, subject to antitrust clearance and a stockholder vote.
- Partners and suppliers should expect any shifts in safety reporting, complaint handling and supply duties to come after the first-quarter 2027 target at the earliest.
Company's press release (SEC filing): Heron Therapeutics, Inc. /De/ ↗
Written by CompePharma's editorial system from the company's filing; claims are the company's. AI-assisted; check the source before acting. Not investment advice.
MacroGenics reports $288M cash and 2028 runway, putting B7-H3 ADC MGC026 in head and neck cancer first
Xenetic reports Q3 loss, advances all-stock Santersus deal and doses first DNase I CAR-T patient
Longeveron seeks FDA meeting after ELPIS II miss and starts strategic alternatives review
Silence Therapeutics narrows Q3 loss as Merck KGaA deal and divesiran data take centre stage
Theriva Sells SYN-004 Antibiotic-Enzyme Assets to Biossil Labs for $350,000 Upfront
